Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has provided an announcement.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced the current composition of its board of directors, which includes executive, non-executive, independent non-executive and an employee director, led by Chairman, CEO and General Manager Dr. Shen Yuelei. The company also detailed the membership of its four key board committees—Audit, Remuneration and Evaluation, Nomination, and Strategy Development—clarifying which directors serve as chairpersons or members, a move that enhances transparency around corporate governance and delineates oversight responsibilities for stakeholders.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a China-incorporated biopharmaceutical company listed in Hong Kong under stock code 2315. The company operates with a structured governance framework comprising executive, non-executive, independent non-executive and employee directors, supported by multiple specialized board committees to oversee audit, remuneration and evaluation, nomination and strategic development matters.
Average Trading Volume: 931,127
Technical Sentiment Signal: Hold
Current Market Cap: HK$13.85B
See more insights into 2315 stock on TipRanks’ Stock Analysis page.